The Effects of Pulmonary Hypertension Web-Based Health Care Program on Symptom Management, Social Support, Activity Tolerance, and Quality of Life in Patients With Pulmonary Hypertension.

Not Applicable

Recruiting

• Conditions: Web-based Health Care Program
• Interventions: Other: Web-based health care program

• Registration Number: NCT05908019
• Lead Sponsor: National Defense Medical Center, Taiwan

Brief Summary

Pulmonary arterial hypertension (PAH) is a chronic disease characterized by an elevation in pulmonary artery pressures and pulmonary vascular resistance. The condition most often is rarely detected, and patients frequently suffer symptoms for several years before being appropriately diagnosed. Patients with PH suffer from several symptoms, such as exertional dyspnea, fatigue, weakness, chest pain, fainting...et al. Pulmonary hypertension is an incurable and progressive disease with complex symptoms and treatments. Patients must learn to deal with their unpredictable future and manage the complex treatments associated with severe adverse effects and need significant changes in lifestyle.

Therefore, it is important to assist patients to develop the ability of symptom management.

Detailed Description

Not available

Study Timeline

• Study Start: 2023-05-05
• Status Verified: 2023-06
• Study First Submitted: 2023-06-01
• Study First Submitted QC: 2023-06-10
• Last Update Submitted: 2023-06-10
• Study First Posted: 2023-06-18
• Last Update Posted: 2023-06-18
• Primary Completion: 2024-12-31
• Study Completion: 2024-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. At least 20 years old, diagnosed by clinical specialists as patients with pulmonary hypertension (Group1 and Group 4)
2. Clear consciousness, able to communicate in Mandarin and Taiwanese, with normal hearing
3. Those who have internet or mobile internet at home
4. Adults without mental illness
5. No alcohol or drug abusers.

Exclusion Criteria

1. critical disease

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Web-based health care program	Web-based health care program	We aim to develop a PAH web-based health care program, and to evaluate the effects of this program on ameliorating social support, self-care ability and active tolerance, and improving symptom distress, anxiety, depression and quality of life in patients with PAH.

Primary Outcome Measures

Name	Time	Method
Pulmonary Arterial Hypertension Symptom	Change from Baseline pulmonary Arterial Hypertension Symptom at six months	Pulmonary Arterial Hypertension Symptom Interference Scale, PAHSS, The 10-point Likert scale higher scores mean a worse outcome.

Secondary Outcome Measures

Name	Time	Method
Pulmonary Hypertension Quality of life	Change from Baseline quality of life at six months	The Cambridge Pulmonary Hypertension Outcome Review, (CAMPHOR). The 5-point Likert scale higher scores mean a better outcome.
Activity ability	Change from Baseline activity ability at six months	6 Minute walk test, 6MWD
Social support	Change from Baseline social support at six months	Multidimensional Scale of Perceived Social Support, (MSPSS). The 7-point Likert scale higher scores mean a better outcome.This instrument is 12 questions long and has been widely used and well validated.

Trial Locations

Locations (1)

Tri-Service General Hospital; 🇨🇳 Taipei, Taiwan, Taipei, Taiwan